Login to Your Account

FDA: Biosimilars Are About Similarity & Not Safety, Efficacy

By Mari Serebrov
Washington Editor

Thursday, August 9, 2012

Sponsors of biosimilars must demonstrate similarity, not safety and efficacy, FDA officials reiterated as they discussed ways to do that at an advisory committee meeting Wednesday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription